January 19, 2018 / 12:19 PM / 6 months ago

BRIEF-Merck says First-Time Data For Keytruda In Patients With Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 ASCO GI Symposium

Jan 19 (Reuters) - Merck & Co Inc:

* FIRST-TIME DATA FOR MERCK'S KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TO BE PRESENTED AT 2018 ASCO GI SYMPOSIUM

* MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES

* MERCK & CO INC - SEVEN PATIENTS DISCONTINUED TREATMENT DUE TO TREATMENT-RELATED ADVERSE EVENTS

* MERCK & CO INC - THERE WAS ONE TREATMENT-RELATED DEATH IN THE STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below